Search clinical trials for: Mixed Dyslipidemia

Total 5790 results

IlDong Pharmaceutical Co Ltd

Completed

Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia

Mixed Dyslipidemias

Korea, Republic of
Mansoura University

Unknown

Vitamin D Supplementation for Treatment of Dyslipidemia

Dyslipidemias

Egypt
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events (SPIRE-LDL)

Hyperlipidemia

United States, Spain, Taiwan, United Kingdom, Canada, Mexico, France, Hungary, Lithuania, Colombia, Romania, Russian Federation
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-LL)

Hyperlipidemia

Finland, Netherlands, United States, Canada, Sweden, Korea, Republic of, Singapore, Czechia, Poland, United Kingdom, Puerto Rico, Norway
SingHealth Polyclinics
Agency for Science, Technology and Research

Unknown

Health Outcomes of Patients With Stable Chronic Disease Managed With a Healthcare Kiosk

Hypertension | Diabetes Mellitus | Hyperlipidemia; Mixed

Singapore
Huazhong University of Science and Technology

Unknown

The Effect of n-3 PUFA Plant Oil Intake on Human Metabolism (PUFA)

Hyperlipidemias

China
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Dyslipidemia

United States, Australia, Brazil, Finland, Germany, Israel, Italy, Kuwait, Lebanon, Norway, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom
Eli Lilly and Company

Completed

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Dyslipidemia

United States, Netherlands, Germany, Denmark, Poland, United Kingdom
Pfizer

Completed

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia (SPIRE-AI)

Hyperlipidemia

United States
Pfizer

Withdrawn

Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects (SPIRE-ASIA)

Primary Hyperlipidemia or Mixed Dyslipidemia

China
Pfizer

Completed

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-HR)

Hyperlipidemia

Korea, Republic of, United States, Australia, Germany, Poland, Canada, Italy, Hong Kong, Czech Republic
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy Study (0524B-022)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Novartis

Completed

Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia

Hypercholesterolemia | Mixed Dyslipidemia

China
Merck Sharp & Dohme LLC

Completed

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

Hyperlipidemia | Hypercholesteremia
Merck Sharp & Dohme LLC

Completed

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

Hypercholesterolemia | Hyperlipidemia
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Action to Control Cardiovascular Risk in Diabetes (ACCORD) (ACCORD)

Cardiovascular Diseases | Coronary Disease | Hypertension | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Atherosclerosis | Hypercholesterolemia

United States, Canada
The Hospital for Sick Children

Completed

Motivational Interviewing With Dyslipidemic Adolescents Together With a Parent Versus With Adolescents Alone: A Mixed Methods Clinical Trial

Dyslipidemias
Cortria Corporation
Montreal Heart Institute

Completed

A Pilot Study to Evaluate the Lipid Effects of TRIA-662

Hypertriglyceridemia | Mixed Hyperlipidemia

Canada
Amgen

Completed

Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk (AMG145)

Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events

Japan
Nordic Pharma, USA
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Withdrawn

Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction (PrOteCT)

Mixed Hyperlipoproteinemia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Pronova BioPharma

Terminated

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

Dyslipidemia

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Lipid Metabolism Disorders

China
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy/Tolerability Study (0524A-020)

Primary Hypercholesterolaemia | Mixed Hyperlipidaemia
Merck Sharp & Dohme LLC

Terminated

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

Hypercholesterolemia | Mixed Dyslipidemia
Daiichi Sankyo, Inc.

Completed

Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol

Hypercholesterolemia | Hyperlipidemia, Familial Combined

United States
Instituto Nacional de Ciencias Medicas y Nutricion...
Merck Sharp & Dohme LLC

Withdrawn

Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors

Cardiovascular Diseases | Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Terminated

MK0859 Dose-Ranging Study (0859-003)

Hypercholesterolemia | Mixed Hyperlipemia
Merck Sharp & Dohme LLC

Completed

A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Hypercholesterolemia | Hyperlipidemia
Chong Kun Dang Pharmaceutical

Unknown

Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin

Mixed Hyperlipidemia

Korea, Republic of
Sang Hak Lee

Unknown

Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid (AVOCADO)

Mixed Hyperlipidemia

Korea, Republic of
University of California, Davis

Withdrawn

Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART (HIV)

HIV Infections | Exercise | Hyperlipidemia

United States
Kowa Research Institute, Inc.

Completed

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia (PREVAIL-US)

Mixed Dyslipidemia | Primary Dyslipidemia

United States
Bristol-Myers Squibb

Completed

Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia

Dyslipidemia

United States, Canada
Pfizer

Terminated

Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)

Mixed Hyperlipidemia

United States, Canada, Czech Republic, Finland, France, Netherlands
Abbott

Completed

A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

Mixed Dyslipidemia

United States
Novartis

Completed

Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia

Mixed Dyslipidemia | Heterozygous Familial Hypercholesterolemia

Switzerland
University of Ioannina

Unknown

Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia

Dyslipidemia

Greece
Abbott

Completed

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

Dyslipidemias | Coronary Heart Disease | Mixed Dyslipidemia | Combined (Atherogenic) Dyslipidemia

United States
Abbott

Completed

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) (SUPREME)

Hyperlipidemia | Mixed Dyslipidemia

United States
National Heart Institute, Mexico

Completed

Effect of Fenofibrate on Endothelial Function and High-density Lipoproteins (HDL)in Patients With Coronary Heart Disease

Coronary Heart Disease | Hyperlipidemia

Mexico
Centre de Recherche en Nutrition Humaine Rhone-Alpe
GlaxoSmithKline; Institut National de la Santé Et de la Recherche Médicale,...

Completed

Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia

Insulin Sensitivity | Lipid Profile | Lipoproteins Metabolism | Non Esterified Fatty Acid Kinetics

France
Abbott

Completed

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

Dyslipidemia | Coronary Heart Disease | Mixed Dyslipidemia

United States
Abbott

Completed

Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

Dyslipidemia | Coronary Heart Disease | Mixed Dyslipidemia

United States
Abbott

Completed

Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

Dyslipidemia | Coronary Heart Disease | Mixed Dyslipidemia

United States
Abbott

Completed

Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

Dyslipidemia | Coronary Heart Disease | Mixed Dyslipidemia

United States
Intermountain Health Care, Inc.
Merck Sharp & Dohme LLC; Abbott

Completed

Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study

Type II Diabetes Mellitus | Mixed Dyslipidemia

United States
Provident Clinical Research
Reliant Pharmaceuticals

Unknown

An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin

Mixed Dyslipidemia

3

Subscribe